Evidence map›Paper›PMID 36556135›Full record

ArticleJournal of clinical medicine2022

New Insights Regarding Hemin Inhibition of the Purified Rat Brain 2-Oxoglutarate Carrier and Relationships with Mitochondrial Dysfunction.

Daniela Valeria Miniero, Nicola Gambacorta, Anna Spagnoletta, Vincenzo Tragni, Stefano Loizzo, Orazio Nicolotti, Ciro Leonardo Pierri, Annalisa De Palma

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Daniela Valeria MinieroDepartment of Biosciences, Biotechnologies and Environment, University "Aldo Moro" of Bari, Via E. Orabona, 4, 70125 Bari, Italy.ORCID 0000-0002-3324-9692
Nicola GambacortaDepartment of Pharmacy-Pharmaceutical Sciences, University "Aldo Moro" of Bari, Via E. Orabona, 4, 70125 Bari, Italy.ORCID 0000-0003-1965-1519
Anna SpagnolettaENEA Italian National Agency for New Technologies, Energy and Sustainable Economic Development, Trisaia Research Centre, S.S. 106 Jonica, Km 419,500, 75026 Rotondella (MT), Italy.ORCID 0000-0003-2767-3910
Vincenzo TragniDepartment of Pharmacy-Pharmaceutical Sciences, University "Aldo Moro" of Bari, Via E. Orabona, 4, 70125 Bari, Italy.
Stefano LoizzoDepartment of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Roma, Italy.
Orazio NicolottiDepartment of Pharmacy-Pharmaceutical Sciences, University "Aldo Moro" of Bari, Via E. Orabona, 4, 70125 Bari, Italy.ORCID 0000-0001-6533-5539
Ciro Leonardo PierriDepartment of Pharmacy-Pharmaceutical Sciences, University "Aldo Moro" of Bari, Via E. Orabona, 4, 70125 Bari, Italy.ORCID 0000-0003-1816-548X
Annalisa De PalmaDepartment of Biosciences, Biotechnologies and Environment, University "Aldo Moro" of Bari, Via E. Orabona, 4, 70125 Bari, Italy.ORCID 0000-0001-6391-529X
University of Bari Aldo Moro · ITIstituto Superiore di Sanità · ITNational Agency for New Technologies, Energy and Sustainable Economic Development · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A kinetic analysis of the transport assays on the purified rat brain 2-oxoglutarate/malate carrier (OGC) was performed starting from our recent results reporting about a competitive inhibitory behavior of hemin, a physiological porphyrin derivative, on the OGC reconstituted in an active form into proteoliposomes. The newly provided transport data and the elaboration of the kinetic equations show evidence that hemin exerts a mechanism of partially competitive inhibition, coupled with the formation of a ternary complex hemin-carrier substrate, when hemin targets the OGC from the matrix face. A possible interpretation of the provided kinetic analysis, which is supported by computational studies, could indicate the existence of a binding region responsible for the inhibition of the OGC and supposedly involved in the regulation of OGC activity. The proposed regulatory binding site is located on OGC mitochondrial matrix loops, where hemin could establish specific interactions with residues involved in the substrate recognition and/or conformational changes responsible for the translocation of mitochondrial carrier substrates. The regulatory binding site would be placed about 6 Å below the substrate binding site of the OGC, facing the mitochondrial matrix, and would allow the simultaneous binding of hemin and 2-oxoglutarate or malate to different regions of the carrier. Overall, the presented experimental and computational analyses help to shed light on the possible existence of the hemin-carrier substrate ternary complex, confirming the ability of the OGC to bind porphyrin derivatives, and in particular hemin, with possible consequences for the mitochondrial redox state mediated by the malate/aspartate shuttle led by the mitochondrial carriers OGC and AGC.

Indexed as

2-oxoglutarate carrierinduced-fit molecular dockingkinetic studymitochondrial carrier regulatory motifmitochondrial dysfunctionporphyrin derivatives

Identifiers

PMID36556135
PMCPMC9785169
OpenAlexW4312209877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.